HuGE Literature Finder
Records
1
-
21
| Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Jun . Akamatsu Hiroaki, Murakami Haruyasu, Harada Hideyuki, Shimizu Junichi, Hayashi Hidetoshi, Daga Haruko, Hasegawa Yoshikazu, Kim Young Hak, Kato Terufumi, Tokunaga Shoji, Nishimura Yasumasa, Yamamoto Nobuyuki, Nakagawa Kazuhi |
| Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pacific journal of cancer prevention : APJCP 2021 May 22 (5): 1581-1590. Vu Thanh Ha, Nguyen Hoa Thi Thai, Dao Linh Khanh, Duong Chi Khanh, Nguyen Cao Van, Doan Tuyet Thi, Nguyen Hang Thi Thuy, Hoang Hung Huy, Dinh Dung Khac, Le Giang Vinh, Vu Thanh Thi, Truong Minh Cong, Nguyen Long Tha |
| Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020 Oct 1078155220964895. Celik Emir, Samanci Nilay Sengul, Karadag Mehmet, Demirci Nebi Serkan, Cikman Duygu Ilke, Derin Sumeyra, Bedir Sahin, Degerli Ezgi, Oruc Kerem, Oztas Nihan Senturk, Demirelli Fuat Hulu |
| Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. Oncology research 2019 Oct . Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuank |
| Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
| A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
| Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer research 2016 Sep 36 (9): 4951-4. Inomata Minehiko, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Yamada Toru, Miwa Toshiro, Hayashi Ryuji, Kashii Tatsuhiko, Matsui Shoko, Tobe Kazuyu |
| Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Oncotarget 2016 May . Zhang Minghui, Guo Hongsheng, Zhao Shu, Wang Yan, Yang Maopeng, Yu Jiawei, Yan Yubo, Wang Y |
| Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
| Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO open 2016 1 (6): e000086. Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro A R, Rachiglio A M, Lambiase M, Latiano T P, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello |
| Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology 2015 Feb 16 (2): 141-51. Yang James Chih-Hsin, Wu Yi-Long, Schuler Martin, Sebastian Martin, Popat Sanjay, Yamamoto Nobuyuki, Zhou Caicun, Hu Cheng-Ping, O'Byrne Kenneth, Feng Jifeng, Lu Shun, Huang Yunchao, Geater Sarayut L, Lee Kye Young, Tsai Chun-Ming, Gorbunova Vera, Hirsh Vera, Bennouna Jaafar, Orlov Sergey, Mok Tony, Boyer Michael, Su Wu-Chou, Lee Ki Hyeong, Kato Terufumi, Massey Dan, Shahidi Mehdi, Zazulina Victoria, Sequist Lecia |
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
| A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
| Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. OncoTargets and therapy 2013 6 803-9. Kader Yasser Abdel, Le Chevalier Thierry, El-Nahas Tamer, Sakr A |
| A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) 2012 Dec . Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, Kim HR, Chang H, Kim JH, Tania C, Cho BC |
| Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 May 7 (5): 856-65. Pietanza M Catherine, Gadgeel Shirish M, Dowlati Afshin, Lynch Thomas J, Salgia Ravi, Rowland Kendrith M, Wertheim Michael S, Price Katharine A, Riely Gregory J, Azzoli Christopher G, Miller Vincent A, Krug Lee M, Kris Mark G, Beumer Jan H, Tonda Margaret, Mitchell Ben, Rizvi Naiyer |
| Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Dec 22 (12): 2610-5. Iqbal S, Goldman B, Fenoglio-Preiser C M, Lenz H J, Zhang W, Danenberg K D, Shibata S I, Blanke C |
| Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Oct 28 (30): 4609-15. Johnson Faye M, Bekele B Nebiyou, Feng Lei, Wistuba Ignacio, Tang Xi Ming, Tran Hai T, Erasmus Jeremy J, Hwang Li-Ling, Takebe Naoko, Blumenschein George R, Lippman Scott M, Stewart David |
| A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 16 (11): 3078-87. Lind Joline S W, Dingemans Anne-Marie C, Groen Harry J M, Thunnissen Frederik B, Bekers Otto, Heideman Daniëlle A M, Honeywell Richard J, Giovannetti Elisa, Peters Godefridus J, Postmus Pieter E, van Suylen Robert Jan, Smit Egbert |
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet. Oncology 2010 Feb 11 (2): 121-8. Mitsudomi Tetsuya, Morita Satoshi, Yatabe Yasushi, Negoro Shunichi, Okamoto Isamu, Tsurutani Junji, Seto Takashi, Satouchi Miyako, Tada Hirohito, Hirashima Tomonori, Asami Kazuhiro, Katakami Nobuyuki, Takada Minoru, Yoshioka Hiroshige, Shibata Kazuhiko, Kudoh Shinzoh, Shimizu Eiji, Saito Hiroshi, Toyooka Shinichi, Nakagawa Kazuhiko, Fukuoka Masahiro, |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: